Back to Education Zone


From publication to practice: How trial data translate to clinical use of CDK4/6 inhibitors in patients with HR+ HER2- advanced breast cancer



Watch leading international experts in breast cancer discuss the latest findings relating to overall survival (OS) with CDK4/6 inhibitors in HR+/ HER2- advanced breast cancer and address the recommendations and practical issues relating to these treatments in daily practice.

Prof. Dr. Sherko Kümmel, Kliniken Essen-Mitte, Germany, discusses the implications of the OS data for CDK4/6 inhibitors reported in clinical trials for daily practice.

Dr Sara Hurvitz, University of California, Los Angeles (UCLA), USA, addresses the factors that can help determine which CDK4/6 inhibitor to prescribe for which patient.

Prof. Dr. med. Peter Fasching, Comprehensive Cancer Center Erlangen-EMN, Germany, provides insights into the quality of life with CDK4/6 inhibitors and approaches to optimizing adherence and managing adverse events in clinical practice.

This activity is intended for oncologists and oncology nurses involved in the treatment of patients with breast cancer.

Learning Objectives

After accessing the touchEXPERT OPINIONS activity, the audience should be better able to:

  • Identify patients with HR+/HER2- advanced breast cancer suitable for treatment with a CDK4/6 inhibitor
  • Understand the key differences between the CDK4/6 inhibitors and how these might influence drug choice for individual patients
  • Apply knowledge of the CDK4/6 inhibitor’s dosing, safety profile and monitoring requirements to optimize patient management

Please feedback on this touchEXPERT OPINIONS on the following:
(scale 1-5, 1 strongly disagree; 5 strongly agree).